{
    "clinical_study": {
        "@rank": "161621", 
        "arm_group": [
            {
                "arm_group_label": "Healthy Volunteers", 
                "arm_group_type": "Other", 
                "description": "Skin Taping (4 samples from normal skin; photograph of taping sites); Blood Sampling; Optional Biopsy (\u22653 participants)"
            }, 
            {
                "arm_group_label": "Discoid Lupus Erythematosus", 
                "arm_group_type": "Other", 
                "description": "Skin Taping (4 samples from unaffected &amp; 4 samples from lesional skin; photograph of taping sites); Blood Sampling; Optional Biopsy (\u22656 participants)"
            }
        ], 
        "brief_summary": {
            "textblock": "The main objectives of the study are as follows:  To determine if ribonucleic acid (RNA)\n      recovery from tape harvesting allows for the identification of a lupus gene signature (e.g.,\n      interferon [IFN] signature) or other biomarkers that may differentiate lupus from normal or\n      nonlesional skin; To determine if the lupus gene signature is differentially expressed in\n      the epidermis from active discoid lesions when compared with unaffected skin from the same\n      participants and from the skin of healthy volunteers (HVs);  To correlate the levels of\n      transcripts of targeted genes obtained in the skin by tape harvesting with those obtained\n      from the blood."
        }, 
        "brief_title": "Pilot Tape Harvesting Study", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Healthy", 
            "Lupus Erythematosus, Discoid"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Lupus Erythematosus, Discoid", 
                "Lupus Erythematosus, Systemic"
            ]
        }, 
        "detailed_description": {
            "textblock": "No study drug is administered as part of this study.  All participants with lupus will be\n      treated according to standard clinical practice."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Healthy volunteers must be in good overall health as determined by the Investigator,\n             based on medical history, physical examination (per standard dermatology practice),\n             and vital signs.\n\n          -  Subjects with lupus must present with active lupus discoid skin disease (with or\n             without systemic manifestations of systemic lupus erythematosus (SLE), as defined by\n             \u22654 out of 11 classification criteria for SLE, as determined by a board-certified\n             dermatologist or rheumatologist, at the time of entry.\n\n        Key Exclusion Criteria:\n\n          -  History of any clinically significant medical condition, other than active lupus\n             discoid skin disease or SLE, as determined by the Investigator, that may impact study\n             analyses, including, but not limited to: History of human immunodeficiency virus;\n             History of hepatitis C virus or hepatitis B virus; Symptoms of bacterial or viral\n             infection (including skin infection) within 14 days prior to the Day 1 Visit\n\n          -  History of malignancy in the last 5 years (nonmelanoma skin cancer that is considered\n             cured by the Investigator will not be exclusionary)\n\n          -  Female subjects who are pregnant or currently breastfeeding.\n\n          -  History of severe allergic or anaphylactic reactions or history of allergic reactions\n             likely to be exacerbated by tape harvesting (e.g., allergy to adhesives).\n\n          -  Current enrollment in any other drug, biologic, or clinical study.\n\n          -  If undergoing skin biopsy, history of allergy or other adverse reaction to local\n             anesthetics that will be used in the study.\n\n          -  Subjects with discoid skin lesions will be excluded from study entry if Evidence of\n             skin conditions other than lupus skin disease (e.g., eczema, psoriasis) that, in the\n             opinion of the Investigator, would interfere with the study execution or analysis.\n\n          -  Change in antimalarial or systemic immunosuppressive dosing regimen within 28 days\n             before the Day 1 Visit.\n\n          -  Exposure to monoclonal antibodies, cytokines, growth factors, soluble receptors,\n             other recombinant products, or fusion proteins for diseases other than SLE within 3\n             months prior to the Day 1 Visit.\n\n          -  Treatment with prednisone at a daily oral dose >15 mg, or equivalent. Any prednisone\n             regimen must be stable for at least 28 days before the Day 1 Visit.\n\n          -  Treatment with any of the following medications within 3 months prior to the Day 1\n             Visit: Cyclophosphamide, Any biologics (e.g., fusion proteins, therapeutic proteins,\n             or monoclonal antibodies) for SLE, including but not limited to belimumab or\n             rituximab.\n\n          -  Treatment with high potency topical steroid and/or other topical agents (e.g.,\n             topical tacrolimus, pimecrolimus) to the skin lesions of interest within 10 days\n             prior to the Day 1 Visit.\n\n        NOTE:  Other protocol-defined inclusion/exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02125695", 
            "org_study_id": "999LE003"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Discoid Lupus Erythematosus", 
                    "Healthy Volunteers"
                ], 
                "description": "skin taping from affected and unaffected sites (4 tape harvestings/area)", 
                "intervention_name": "Skin Taping", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": [
                    "Discoid Lupus Erythematosus", 
                    "Healthy Volunteers"
                ], 
                "description": "sampling for biomarker and basic research in SLE/DLE", 
                "intervention_name": "Blood Sampling", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": [
                    "Discoid Lupus Erythematosus", 
                    "Healthy Volunteers"
                ], 
                "description": "Optional Skin biopsies from at least 9, but not more than 12 participants", 
                "intervention_name": "Skin Biopsy", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 25, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Pilot Study to Evaluate Using Tape Harvesting to Collect RNA From the Upper Epidermis of Healthy Volunteers and Subjects With Discoid Lupus", 
        "overall_contact": {
            "email": "clinicaltrials@biogenidec.com", 
            "last_name": "Biogen Idec Investigator"
        }, 
        "overall_official": {
            "affiliation": "Biogen Idec", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Comparison of RNA expression of genes suspected to be associated with discoid lupus in affected versus unaffected skin in participants with discoid lupus erythematosus (DLE)", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "measure": "Comparison of RNA expression of genes suspected to be associated with discoid lupus in healthy skin from HVs versus affected skin from participants with DLE", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "measure": "Comparison of RNA expression of genes suspected to be associated with discoid lupus in healthy skin from HVs versus unaffected skin from participants with DLE", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "measure": "the correlation between expression levels obtained from tape harvesting and those obtained from blood samples for each identified gene", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02125695"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Biogen Idec", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biogen Idec", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}